The S&P Global France Manufacturing Purchasing Managers’ Index posted 50.0 in March,marking little change from February's 50.1 and therefore signalling stagnant operating conditions across France's goods-producing economy. The figure was lower than estimated 50.2. "The March PMI revealed an immediate impact from the war in the Middle East. The survey data, collected between 12-24 March, imply a ra...
The S&P Global France Manufacturing Purchasing Managers’ Index posted 50.0 in March,marking little change from February's 50.1 and therefore signalling stagnant operating conditions across France's goods-producing economy. The figure was lower than estimated 50.2. "The March PMI revealed an immediate impact from the war in the Middle East. The survey data, collected between 12-24 March, imply a rapid supply-side squeeze from the conflict as delivery times lengthened substantially and input costs soared. The passthrough to output prices appears to be fairly contained at this stage. This could be due to an unfavourable demand environment limiting French producers' pricing power, although firms may also be stalling price increases in the hope that there is a quick resolution to the war that brings with it a normalisation of supply and price conditions." said Joe Hayes, Principal Economist at S&P Global Market Intelligence. More on France U.S. Tariffs: A New Trade War? EWQ: Falling Real Rates Delayed The Bear Case, But 2026 May Not ‘Mr. Brexit’ strategist nails winning calls as Iran conflict erupts Euro Area inflation rises to 2.5% in March Seeking Alpha’s Quant Rating on iShares MSCI France ETF
Nvidia (NASDAQ: NVDA) has been one of the best-performing stocks in the market for the past five years, up 1,220% over that period. That has helped it grow to become the largest company in the world , with a market capitalization (market cap) of over $4.1 trillion. Nvidia's rise to the mountaintop is well deserved. The company has just seen explosive growth over the past several years. Its revenue...
Nvidia (NASDAQ: NVDA) has been one of the best-performing stocks in the market for the past five years, up 1,220% over that period. That has helped it grow to become the largest company in the world , with a market capitalization (market cap) of over $4.1 trillion. Nvidia's rise to the mountaintop is well deserved. The company has just seen explosive growth over the past several years. Its revenue has gone from $16.7 billion in fiscal 2021 (ending January 2022) to $215.9 billion last fiscal year. That's nearly a 13 times increase in revenue in just five years. However, it is how the company has been able to evolve over the years that makes its stock a buy today. Image source: The Motley Fool. Continue reading
When gas prices rise, it isn't just oil companies that benefit. Costco and BJ's both benefit from high fuel prices, and their stocks look poised for growth.
When gas prices rise, it isn't just oil companies that benefit. Costco and BJ's both benefit from high fuel prices, and their stocks look poised for growth.
Earnings Call Insights: Omeros Corporation (OMER) Q4 2025 Management View "Two major successes made the fourth quarter of 2025 a turning point for Omeros." (Co-Founder, Chairman, CEO & President Gregory Demopulos) "On November 25, we closed our previously announced asset purchase and license transaction with Novo Nordisk for our Phase III ready asset, zaltenibart." (CEO Demopulos) He said the deal...
Earnings Call Insights: Omeros Corporation (OMER) Q4 2025 Management View "Two major successes made the fourth quarter of 2025 a turning point for Omeros." (Co-Founder, Chairman, CEO & President Gregory Demopulos) "On November 25, we closed our previously announced asset purchase and license transaction with Novo Nordisk for our Phase III ready asset, zaltenibart." (CEO Demopulos) He said the deal brought "$240 million" upfront, plus "$100 million in achievable near-term milestones," and additional milestones and royalties, adding, "All told, the deal is valued at up to $2.1 billion in upfront and milestone payments." (CEO Demopulos) "On December 23, we received FDA approval for narsoplimab now commercialized under the brand name YARTEMLEA" for TA-TMA, and Demopulos emphasized the label: "Specifically, no box warning, no risk evaluation and mitigation strategy or REMS program and no required vaccinations." (CEO Demopulos) Demopulos said commercialization started quickly: "Having supplied our distributors within the first 3 weeks of January, first sales occurred shortly thereafter." He also stated operational execution metrics: "Within 24 hours of placing an order, both adult and pediatric TA-TMA patients are now receiving YARTEMLEA." (CEO Demopulos) On early launch traction, management disclosed formulary penetration: YARTEMLEA was "now on formulary at 50% of the top 10 U.S. transplant centers, 40% of the top 20 centers, 35% of the top 40 centers and approximately 30% of the top 80 transplant centers." (CEO Demopulos) "This charge represents a noncash remeasurement adjustment and excluding it, provides a clearer view of the company's operating performance during the quarter." (VP of Finance, Chief Accounting Officer & Treasurer David Borges) Outlook Management said it is not providing near-term sales targets: "As YARTEMLEA is in the early stages of launch, we are not providing revenue guidance at this time." (Chief Accounting Officer Borges) Near-term expense trajec...